Overview
Sean McClain is the founder and chief executive officer of Absci Corporation, a clinical-stage biotechnology company headquartered in Vancouver, Washington that designs breakthrough therapeutics using generative artificial intelligence. Absci’s team page describes McClain as pioneering a new era of medicine at the intersection of AI and biology to design life-changing drugs.
Absci is publicly traded on NASDAQ (ABSI) and describes its approach as Integrated Drug Creation — combining computational design with laboratory execution to move AI-generated antibody candidates into clinical development.
Role and company
McClain serves as Founder, CEO, and Director, leading Absci’s corporate strategy and AI drug creation platform. The company’s leadership page states his journey reflects a deep belief that the future of health lies in merging human ingenuity with machine intelligence. Absci envisions moving beyond managing symptoms to restoring the body’s innate capacity to heal itself, making curing disease a matter of design rather than luck.
Under McClain, Absci has advanced AI-designed therapeutic candidates including ABS-101, an anti-TL1A antibody that entered Phase 1 clinical trials per investor relations releases cited in company materials.
Background and career context
Absci’s official team biography states McClain built the company from a 400 square foot basement lab to an industry-leading biotech platform. The narrative emphasizes entrepreneurial persistence at the intersection of machine learning and protein engineering rather than a traditional large-pharma executive path.
McClain’s personal detail on the team page — an interest in chess and weekend BBQ — reflects the company’s culture-forward leadership presentation, though clinical and partnership milestones remain the verifiable public record for investors and hospital partners.
Company-building or leadership context
McClain founded Absci in 2011 per company investor relations and about materials. He has remained the consistent founder-CEO voice through Absci’s evolution from discovery platform vendor to clinical-stage biotech with its own pipeline. Absci’s board and executive team include CFO Zach Jonasson, PhD, and CMO Ransi Somaratne, MD, reflecting the clinical development scale McClain’s leadership now requires.
Partnership announcements with pharmaceutical companies including Almirall for dermatology targets demonstrate Absci’s dual model: internal pipeline progress plus partner-funded AI drug creation.
Public milestones
Absci announced first participants dosed in a Phase 1 trial of ABS-101, an AI-designed anti-TL1A antibody for inflammatory bowel disease, in a May 13, 2025 investor relations release. The company reported expanded AI drug creation collaborations with Almirall in August 2025 per its news timeline.
McClain is identified as Founder and CEO in these releases, confirming his operating role through clinical-stage transition — a milestone few AI discovery platforms reach under founding CEOs.
Why their work matters
Absci matters because it tests whether generative AI can produce developable biologics that reach human trials faster than traditional discovery — not merely generate in silico candidates that fail in the lab. McClain’s basement-to-Phase-1 narrative gives drug-discovery AI a concrete clinical proof point for biotech investors comparing platform companies.
For healthcare AI readers, Absci sits at the biology end of the spectrum — distinct from clinical documentation or imaging AI — but shares the 2026 theme of proving AI outputs survive regulated validation paths.
Sources and references
Primary sourcing: Absci leadership team page and About Us, reviewed July 10, 2026.
- Absci — Team / Sean McClain (absci.com)
- Absci — About Us (absci.com)
Phase 1 dosing milestone sourced from Absci investor relations materials referenced on company pages. No funding or education claims beyond official Absci sources.